Tesa/IPA Protocol Overview, Dosing & Safety | Peptide Database

Tesa/IPA Protocol (Tesa-IPA)

Tesamorelin + Ipamorelin GH Secretagogue Blend

Community Research

Join others researching Tesa/IPA Protocol — share findings, ask questions, and learn from real experiences

The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.

The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.

Molecular Data

Complex or non-standard sequence format

Research Indications

Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.

Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).

Enhanced GH promotes protein synthesis and lean tissue preservation.

GH secretagogues often improve deep sleep quality.

Enhanced GH supports tissue repair and recovery from exercise.

Restoring more youthful GH levels may provide anti-aging benefits.

Tesamorelin has shown improvements in lipid parameters in studies.

Increased GH leads to increased IGF-1 production.

Dosing Protocols

Subcutaneous injection, typically administered before bed or in the morning on an empty stomach. Evening dosing may enhance natural nighttime GH pulse. Avoid eating 2-3 hours before and 30-60 minutes after injection for optimal results.

Standard protocol (5/5 blend)

200-400mcg total

Once daily (evening)

SubQ

Enhanced protocol (10/3 blend)

300-500mcg total

Twice daily (advanced)

200-300mcg per dose

Morning and evening

Reconstitution Instructions

Tesa/IPA vial (5/5mg or 10/3mg)

Bacteriostatic water (2-3mL)

Insulin syringes

Alcohol prep pads

1 Clean vial top with alcohol pad

2 Add 2mL bacteriostatic water for convenient dosing

3 Gently swirl - do not shake

4 Solution should appear clear

5 Label with date and concentration

6 Store refrigerated immediately

7 Use within 4-6 weeks

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Injection site reactions (redness, itching)

Water retention (usually transient)

Tingling or numbness in extremities

Joint stiffness

Increased hunger (Ipamorelin effect)

Stop Signs - Discontinue if:

Severe injection site reactions

Significant swelling or edema

Signs of glucose dysregulation

Severe joint pain

Allergic reactions

Contraindications

Active malignancy (GH may promote tumor growth)

Diabetic retinopathy

Pregnancy or breastfeeding

Pituitary disorders

Hypersensitivity to components

Quality Checklist

Good Signs

Third-party testing confirming both components

Certificate of Analysis with ratios verified

Reputable research supplier

Proper cold chain shipping

Warning Signs

Tesamorelin is FDA-approved as Egrifta - research blends are not

Ipamorelin remains investigational

Bad Signs

No Certificate of Analysis

Cannot verify Tesamorelin:Ipamorelin ratio

Discolored or particulate solution

Frequently Asked Questions

Why combine tesamorelin and ipamorelin instead of using them separately?

Tesamorelin and ipamorelin work on complementary GH-release pathways (GHRH vs GHRP receptors), producing synergistic GH release greater than either alone. The combination mimics natural pulsatile GH secretion more effectively while maintaining safety with less cortisol/prolactin elevation than GHRPs used solo.

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for athletic recovery; 10/3 for fat-loss focused protocols with body composition optimization goals.

Should the Tesa/IPA blend be taken on an empty stomach?

Yes, both tesamorelin and ipamorelin work best on an empty stomach (2-3 hours before eating). Evening injection (before bed) on an empty stomach optimizes the protocol by aligning with natural nighttime GH pulses and avoiding food-induced metabolic interference.

Can Tesa/IPA be combined with CJC-1295 or other GH secretagogues?

No, combining Tesa/IPA (which already contains both GHRH and GHRP pathways) with additional GHRPs or GHRH analogs risks excessive pituitary stimulation. The blend is specifically designed as a complete dual-pathway system that shouldn't require additional GH secretagogues.

References

Landmark RCT in 412 HIV patients: tesamorelin 2 mg daily for 26 weeks reduced visceral fat by 10.9% vs 0.6% placebo, improved lipid profiles with no change in subcutaneous fat.

Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.

Combining GHRH and GHRP pathways produces synergistic GH release greater than either agent alone, driven by independent receptor mechanisms on pituitary somatotrophs.

No clinical trials have evaluated the specific tesamorelin + ipamorelin blend; synergy is inferred from GHRH/GHRP pharmacology and individual component data.

Related Peptides

Different mechanisms; can complement for healing with GH support.

Different pathways; some combine for body composition goals.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.